A new strategy, which three years ago achieved 100% tumor elimination in a dozen patients with rectal cancer, has now achieved outstanding results in another group with cases of esophageal, stomach, colon, liver, bladder, uterus, and prostate cancer. The treatment, known as immunoablative therapy, has achieved the apparent disappearance of cancer in 80% of 100 participants who share a specific genetic mutation. Oncologist Ana Fernández Montes, who was not involved in this research, considers it “a paradigm shift.” The treatment avoids having to resort to other more aggressive alternatives, such as surgery, radiation, or chemotherapy.

Seguir leyendo